Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Denosumab vs Zoledronic Acid Treatment in Post-Menopausal Breast Cancer: A 2-year Prospective Observational Study

Buch-Larsen, K

DOI

10.17632/3xjhghs24g.1

Publisher

Data Archiving and Networked Services (DANS)

Abstract

Source Data with BMD and lab result data - contact authors for further informatio

Extracted data

Topics

Related items

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

Lipton, A.
Fizazi, K.
Stopeck, A.T.
Henry, D.H.
Smith, M.R.
Shore, N.
Martin, M.
Vadhan-Raj, S.
Brown, J.E.
Richardson, G.E.
Saad, F.
Yardley, D.A.
Zhou, K.
Balakumaran, A.
Braun, A.

January 2016

AbstractBackgroundAnalyses of phase III trials showed that denosumab was superior to zoledronic acid...

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

Alexander Paterson

December 2013

Bone loss is common in patients with breast cancer. Bone modifying agents (BMAs), such as bisphospho...

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis

Makras, P.
Papapoulos, S.E.
Polyzos, S.A.
Appelman-Dijkstra, N.M.
Anastasilakis, A.D.

September 2020

Introduction: In women with postmenopausal osteoporosis denosumab discontinuation is associated with...

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Chi Zhang
Fan Zhang
Guanzhao Liang
Xianshang Zeng
Weiguang Yu
Zhidao Jiang
Jie Ma
Mingdong Zhao
Min Xiong
Keke Gui
Fenglai Yuan
Weiping Ji

November 2018

Abstract Background The purpose of this study was to evaluate the efficacy of denosumab or zoledroni...

Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Cleeland, Charles S
Body, Jean-Jacques
Stopeck, Alison
von Moos, Roger
Fallowfield, Lesley J
Mathias, Susan D
Patrick, Donald L
Clemons, Mark J
Tonkin, Katia
Masuda, Norikazu
Lipton, Allan
De Boer, Richard
Salvagni, Stefania
Oliveira, Celia Tosello
Qian, Yi
Jiang, Qi
Dansey, Roger
Braun, Ada
Chung, Karen

February 2013

In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in ...

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck, Alison T
Lipton, Allan
Body, Jean-Jacques
Steger, Guenther G
Tonkin, Katia
de Boer, Richard H
Lichinitser, Mikhail
Fujiwara, Yasuhiro
Yardley, Denise A
Viniegra, María
Fan, Michelle
Jiang, Qi
Dansey, Roger
Jun, Susie
Braun, Ada

December 2010

This randomized study compared denosumab, a fully human monoclonal antibody against receptor activat...

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study.

Stanoyevitch, Alexander
Zhang, Lei
Sanz, Javier
Follett, Robert W
Bell, Douglas S

January 2021

Background: The risks of osteoporosis and breast cancer are increasing in elderly women. Bisphosphon...

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study

August 2021

Background: The risks of osteoporosis and breast cancer are increasing in elderly women. Bisphosphon...

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

Roux, C
Hofbauer, LC
Ho, PR
Wark, JD
Zillikens, M.C.
Fahrleitner-Pammer, A
Hawkins, F
Micaelo, M
Minisola, S
Papaioannou, N
Stone, M
Ferreira, I
Siddhanti, S
Wagman, RB
Brown, JP

January 2014

Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal ...

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Stopeck, Alison
Tonkin, Katia
Shore, Neal
Sieber, Paul
Kueppers, Frank
Karsh, Lawrence
Yardley, Denise
Wang, Huei
Maniar, Tapan
Arellano, Jorge
Braun, Ada
Fizazi, Karim
Body, Jean-Jacques
Brown, Janet
Carducci, Michael
Diel, Ingo Jakob
Fujiwara, Yasuhiro
Martin, Miguel
Paterson, Alexander H. G.

January 2016

Purpose: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the s...

Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

Imai, Hiroo
Saijo, Ken
Yamada, Hideharu
Ohuchi, Kota
Okada, Yoshinari
Komine, Keigo
Takahashi, Masahiro
Takahashi, Shin
Takahashi, Masanobu
Shimodaira, Hideki
Ishioka, Chikashi

October 2016

AbstractBackgroundBone is a metastatic site for various types of cancer. Cancer patients in whom bon...

The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation

Makras, P.
Appelman-Dijkstra, N.M.
Papapoulos, S.E.
Wissen, S. van
Winter, E.M.
Polyzos, S.A.
Yavropoulou, M.P.
Anastasilakis, A.D.

October 2021

Context: Zoledronate is used to prevent bone loss following denosumab discontinuation but its effica...

The use of Denosumab for breast cancer patients with bone metastases: experience from a tertiary center

Leung, TW
Lau, J
Kwong, DLW
Yung, ST
Tsang, JWH
Sze, HCK
Chan, A
Luk, MY

January 2014

A total of 43 patients suffering from breast cancer with bone metastases were treated with subcutane...

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials

A. Lipton
K. Fizazi
A.T. Stopeck
D.H. Henry
J.E. Brown
D.A. Yardley
G.E. Richardson
S. Siena
P. Maroto
M. Clemens
B. Bilynskyy
V. Charu
P. Beuzeboc
M. Rader
M. Viniegra
F. Saad
C. Ke
A. Braun
S. Jun

November 2012

Background: Patients with bone metastases from advanced cancer often experience skeletal-related eve...

Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis

Ford, J.A.
Jones, R.
Elders, A.
Mulatero, C.
Royle, P.
Sharma, P.
Stewart, F.
Todd, R.
Mowatt, G.

January 2013

Aim: To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid ...

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

Lipton, A.
Fizazi, K.
Stopeck, A.T.
Henry, D.H.
Smith, M.R.
Shore, N.
Martin, M.
Vadhan-Raj, S.
Brown, J.E.
Richardson, G.E.
Saad, F.
Yardley, D.A.
Zhou, K.
Balakumaran, A.
Braun, A.

January 2016

AbstractBackgroundAnalyses of phase III trials showed that denosumab was superior to zoledronic acid...

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

Alexander Paterson

December 2013

Bone loss is common in patients with breast cancer. Bone modifying agents (BMAs), such as bisphospho...

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis

Makras, P.
Papapoulos, S.E.
Polyzos, S.A.
Appelman-Dijkstra, N.M.
Anastasilakis, A.D.

September 2020

Introduction: In women with postmenopausal osteoporosis denosumab discontinuation is associated with...

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Chi Zhang
Fan Zhang
Guanzhao Liang
Xianshang Zeng
Weiguang Yu
Zhidao Jiang
Jie Ma
Mingdong Zhao
Min Xiong
Keke Gui
Fenglai Yuan
Weiping Ji

November 2018

Abstract Background The purpose of this study was to evaluate the efficacy of denosumab or zoledroni...

Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Cleeland, Charles S
Body, Jean-Jacques
Stopeck, Alison
von Moos, Roger
Fallowfield, Lesley J
Mathias, Susan D
Patrick, Donald L
Clemons, Mark J
Tonkin, Katia
Masuda, Norikazu
Lipton, Allan
De Boer, Richard
Salvagni, Stefania
Oliveira, Celia Tosello
Qian, Yi
Jiang, Qi
Dansey, Roger
Braun, Ada
Chung, Karen

February 2013

In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in ...

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck, Alison T
Lipton, Allan
Body, Jean-Jacques
Steger, Guenther G
Tonkin, Katia
de Boer, Richard H
Lichinitser, Mikhail
Fujiwara, Yasuhiro
Yardley, Denise A
Viniegra, María
Fan, Michelle
Jiang, Qi
Dansey, Roger
Jun, Susie
Braun, Ada

December 2010

This randomized study compared denosumab, a fully human monoclonal antibody against receptor activat...

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study.

Stanoyevitch, Alexander
Zhang, Lei
Sanz, Javier
Follett, Robert W
Bell, Douglas S

January 2021

Background: The risks of osteoporosis and breast cancer are increasing in elderly women. Bisphosphon...

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study

August 2021

Background: The risks of osteoporosis and breast cancer are increasing in elderly women. Bisphosphon...

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

Roux, C
Hofbauer, LC
Ho, PR
Wark, JD
Zillikens, M.C.
Fahrleitner-Pammer, A
Hawkins, F
Micaelo, M
Minisola, S
Papaioannou, N
Stone, M
Ferreira, I
Siddhanti, S
Wagman, RB
Brown, JP

January 2014

Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal ...

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Stopeck, Alison
Tonkin, Katia
Shore, Neal
Sieber, Paul
Kueppers, Frank
Karsh, Lawrence
Yardley, Denise
Wang, Huei
Maniar, Tapan
Arellano, Jorge
Braun, Ada
Fizazi, Karim
Body, Jean-Jacques
Brown, Janet
Carducci, Michael
Diel, Ingo Jakob
Fujiwara, Yasuhiro
Martin, Miguel
Paterson, Alexander H. G.

January 2016

Purpose: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the s...

Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

Imai, Hiroo
Saijo, Ken
Yamada, Hideharu
Ohuchi, Kota
Okada, Yoshinari
Komine, Keigo
Takahashi, Masahiro
Takahashi, Shin
Takahashi, Masanobu
Shimodaira, Hideki
Ishioka, Chikashi

October 2016

AbstractBackgroundBone is a metastatic site for various types of cancer. Cancer patients in whom bon...

The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation

Makras, P.
Appelman-Dijkstra, N.M.
Papapoulos, S.E.
Wissen, S. van
Winter, E.M.
Polyzos, S.A.
Yavropoulou, M.P.
Anastasilakis, A.D.

October 2021

Context: Zoledronate is used to prevent bone loss following denosumab discontinuation but its effica...

The use of Denosumab for breast cancer patients with bone metastases: experience from a tertiary center

Leung, TW
Lau, J
Kwong, DLW
Yung, ST
Tsang, JWH
Sze, HCK
Chan, A
Luk, MY

January 2014

A total of 43 patients suffering from breast cancer with bone metastases were treated with subcutane...

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials

A. Lipton
K. Fizazi
A.T. Stopeck
D.H. Henry
J.E. Brown
D.A. Yardley
G.E. Richardson
S. Siena
P. Maroto
M. Clemens
B. Bilynskyy
V. Charu
P. Beuzeboc
M. Rader
M. Viniegra
F. Saad
C. Ke
A. Braun
S. Jun

November 2012

Background: Patients with bone metastases from advanced cancer often experience skeletal-related eve...

Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis

Ford, J.A.
Jones, R.
Elders, A.
Mulatero, C.
Royle, P.
Sharma, P.
Stewart, F.
Todd, R.
Mowatt, G.

January 2013

Aim: To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid ...

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

Lipton, A.
Fizazi, K.
Stopeck, A.T.
Henry, D.H.
Smith, M.R.
Shore, N.
Martin, M.
Vadhan-Raj, S.
Brown, J.E.
Richardson, G.E.
Saad, F.
Yardley, D.A.
Zhou, K.
Balakumaran, A.
Braun, A.

January 2016

AbstractBackgroundAnalyses of phase III trials showed that denosumab was superior to zoledronic acid...

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

Alexander Paterson

December 2013

Bone loss is common in patients with breast cancer. Bone modifying agents (BMAs), such as bisphospho...

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis

Makras, P.
Papapoulos, S.E.
Polyzos, S.A.
Appelman-Dijkstra, N.M.
Anastasilakis, A.D.

September 2020

Introduction: In women with postmenopausal osteoporosis denosumab discontinuation is associated with...